Inactive Instrument

Share ownership Galapagos NV Euronext Bruxelles

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles Other stock markets
-	-

06-16	Lakefront Biotherapeutics NV commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on April 28, 2026.	CI
06-10	Lakefront Announces Share Buyback Program

Share class: Galapagos NV

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,897,071	49,186,994 ( 74.64 %)	0	74.64 %

Major shareholders: Galapagos NV

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	477 M
EcoR1 Capital, LLC 10.92 %	7,193,777	10.92 %	205 M
Van Herk Investments BV 7.035 %	4,635,672	7.035 %	132 M
Niche Asset Management Ltd. 0.1017 %	67,000	0.1017 %	2 M
Saint Olive Gestion SNC 0.0645 %	42,500	0.0645 %	1 M
Zenito Oy 0.0493 %	32,500	0.0493 %	927 667
Ennismore Fund Management Ltd. 0.0167 %	11,000	0.0167 %	313 980
Gesalcalá SA SGIIC 0.0152 %	10,000	0.0152 %	285 436
Mercer Global Investments Europe Ltd. 0.011 %	7,263	0.011 %	207 312
Keyridge Asset Management Ltd. 0.006504 %	4,286	0.006504 %	122 338
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	474 M
Tang Capital Management LLC 5.745 %	3,785,991	5.745 %	107 M
Madison Avenue Partners LP 5.472 %	3,606,203	5.472 %	102 M
Madison Avenue Partners LP 3.741 %	2,465,179	3.741 %	70 M
EcoR1 Capital, LLC 2.53 %	1,667,119	2.53 %	47 M
Prosight Management LP 2.352 %	1,550,000	2.352 %	44 M
Ameriprise Financial Services LLC 2.162 %	1,424,674	2.162 %	40 M
DME Capital Management LP 0.7326 %	482,746	0.7326 %	14 M
Segall Bryant & Hamill LLC 0.6471 %	426,412	0.6471 %	12 M
Point72 Asset Management LP 0.504 %	332,125	0.504 %	9 M
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Gilead Sciences, Inc.	50.71%
Institutional	44.95%
Others	1.08%
ABC arbitrage SA	0.02%
Individuals	0.01%
Unknown	3.23%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	89.05%
Netherlands	7.07%
Norway	0.14%
United Kingdom	0.12%
France	0.09%
Canada	0.06%
Finland	0.05%
Monaco	0.04%
Cayman Islands	0.04%
Ireland	0.03%
Austria	0.02%
Germany	0.02%
Spain	0.02%
Individuals	0.01%
Denmark	0.01%

Based on 1000 largest holdings

Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company